Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin

Clinical Pharmacology and Therapeutics

Volumn 58, Issue 6, 1995, Pages 617-624

  Ducharme, Murray P ^b   Slaughter, Richard L ^c   Warbasse, Lawrence H ^c   Chandrasekar, Pranatharthi H ^c   Van De Velde, Vera ^c   Mannens, Geert ^c   Edwards, David J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORESCENCE; HALF-LIFE; HUMANS; IMMUNOASSAY; ITRACONAZOLE; MALE; PHENYTOIN; REFERENCE VALUES;

EID: 0029595358     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9236(95)90017-9     Document Type: Article

References (23)

1. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994:330:263-72.
2. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991:32:624-6.
3. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993:269:1513-8.
4. Canafax DM, Graves NM, Hilligoss DM, Carleton BG, Gardner MJ, Matas AJ. Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double blind, randomized pharmacokinetic and safety study. Transplant Proc 1991;23:1041-2.
5. Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992;34:75-8.
6. Lavrijsen K, Van Houdt J, Thijs D, Meuldermans W, Heykants J. Interaction of miconazole, ketoconazole, and itraconazole with rat-liver microsomes. Xenobiotica 1987;17:45-57.
7. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. CLIN PHARMACOL THER 1994;55:481-5.
8. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. CLIN PHARMACOL THER 1994;56:601-7.
9. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
10. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole [Letter]. Lancet 1987;2:282.
11. Tucker RM, Denning DW, Hanson LH, et al. Interactions of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
12. Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1987;413:332-7.
13. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl):67-87.
14. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
15. Thummel KE, Shen DD, Bacchi CE, et al. Induction of human hepatic P450 3A3/4 by phenytoin [Abstract]. Hepatology 1992;16:160A.
16. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part 1). Clin Pharmacokinet 1990;18:37-60.
17. Crowley JJ, Cusack BJ, Jue SG, Koup JR, Vestal RE. Cigarette smoking and theophylline metabolism: effects of phenytoin. CLIN PHARMACOL THER 1987;42:334-40.
18. Chalk JB, Ridgeway K, Brophy TR, Yelland JDN, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984;47:1087-90.
19. Capewell S, Freestone S, Critchley JAJH, Pottage A, Prescott L. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;2:480-2.
20. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
21. Hosteller JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies in interpatient variations in concentrations. Antimicrob Agents Chemother 1993;37:2224-7.
22. Hargreaves JA, Jezequel S, Houston JB. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam [Abstract]. Br J Clin Pharmacol 1994;38:175P.
23. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.